Balyasny Asset Management’s AbbVie ABBV Stock Holding History

Balyasny Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.05M	Buy	28,000 +8,300	+42%	+$1.79M	0.01%	1220
2026 Q1	$4.28M	Sell	19,700 -19,300	-49%	-$4.28M	0.01%	1431
2025 Q4	$8.91M	Sell	39,000 -60,400	-61%	-$13.8M	0.01%	1079
2025 Q3	$23M	Buy	99,400 +69,200	+229%	+$14.1M	0.03%	657
2025 Q2	$5.61M	Sell	30,200 -90,900	-75%	-$16.9M	0.01%	1232
2025 Q1	$25.4M	Buy	121,100 +13,200	+12%	+$2.57M	0.04%	506
2024 Q4	$19.2M	Buy	107,900 +8,600	+9%	+$1.58M	0.03%	691
2024 Q3	$19.6M	Buy	99,300 +52,300	+111%	+$9.76M	0.03%	638
2024 Q2	$8.06M	Sell	47,000 -10,900	-19%	-$1.81M	0.01%	972
2024 Q1	$10.5M	Sell	57,900 -73,600	-56%	-$12.7M	0.02%	901
2023 Q4	$20.4M	Buy	131,500 +11,800	+10%	+$1.72M	0.04%	593
2023 Q3	$17.8M	Buy	+119,700	New	+$17.6M	0.04%	616
2023 Q2	–	Sell	-59,500	Closed	-$9.48M	–	2215
2023 Q1	$9.48M	Sell	59,500 -50,000	-46%	-$7.64M	0.02%	799
2022 Q4	$17.7M	Hold	109,500	–	–	0.05%	533
2022 Q3	$14.7M	Sell	109,500 -123,000	-53%	-$17.7M	0.05%	531
2022 Q2	$35.6M	Buy	232,500 +15,000	+7%	+$2.29M	0.12%	243
2022 Q1	$35.3M	Buy	+217,500	New	+$31.6M	0.11%	236
2021 Q3	–	Sell	-7,300	Closed	-$822K	–	1878
2021 Q2	$822K	Buy	+7,300	New	+$822K	﹤0.01%	1375
2019 Q3	–	Sell	-30,000	Closed	-$2.36M	–	1113
2019 Q2	$2.36M	Buy	+30,000	New	+$2.36M	0.02%	828
2018 Q4	–	Sell	-57,000	Closed	-$5.19M	–	1346
2018 Q3	$5.19M	Buy	+57,000	New	+$5.41M	0.02%	687
2016 Q4	–	Sell	-128,292	Closed	-$86K	–	1328
2016 Q3	$86K	Buy	+128,292	New	+$8.31M	﹤0.01%	929
2015 Q1	–	Sell	-350,000	Closed	-$22.9M	–	922
2014 Q4	$22.9M	Buy	+350,000	New	+$22.1M	0.21%	137

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Balyasny Asset Management's ABBV Position: Q2 2026 in Review

Balyasny Asset Management increased its AbbVie (ABBV) stake by 1,673% in Q2 2026, buying an estimated $126M and bringing the position to 622,946 shares worth $157M. The position accounts for 0.2% of the portfolio, ranked #111.

Balyasny Asset Management first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $240M in Q2 2025. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Balyasny Asset Management held 622,946 shares of AbbVie worth $157M as of Q2 2026.
Balyasny Asset Management bought 587,816 AbbVie shares in Q2 2026, an estimated $126M.
AbbVie made up 0.2% of Balyasny Asset Management's portfolio in Q2 2026, its #111 holding.
Balyasny Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
Balyasny Asset Management's AbbVie position peaked at $240M in Q2 2025.
4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.